

## DAFTAR PUSTAKA

- Allan R.E., Rodriguez P. L., & Porras J. 2016. Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio as Prognostic Factors in Non-Metastatic Breast Cancer Patients from a Hispanic Population. *Breast Disease* -1, hal. 1–6
- American Cancer Society. 2019. *Breast Cancer Facts & Figures 2019-2020*, hal. 3
- Bahgat T. 2017. Breast Cancer Prognostication with Neutrophil–lymphocyte Ratio and Platelet–lymphocyte Ratio. *Al-Azhar Assiut Medical Journal*, 15:179–186
- Bray F. *et al.* 2018. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA CANCER J CLIN* 68: 394–424
- Breast Cancer: a Systematic Review and Meta-analysis of Observational Studies. *BMC*, hal. 1-2
- Budiarto E. 2001. *Biostatistika untuk Kedokteran dan Kesehatan Masyarakat*. Jakarta: EGC, hal 27
- Dahlan , MS. 2010. *Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan*. Seri Evidence Based Medicine 2 Edisi 3. Jakarta: Salemba Medika, hal. 76
- Dahlan, MS. 2010. *Statistik untuk Kedokteran dan Kesehatan*. Seri Evidence Based Medicine 1 Edisi 5. Jakarta: Salemba Medika, hal. 167-171
- Ellis H. & Vishy M. 2013. *Anatomy and Physiology of the Breast*. Elsevier. 11-14
- Fong Y. *et al.* 2015. The Nottingham Prognostic Index: Five- and Ten-Year Data for all-cause Survival within a Screened Population. *Breast Surgery. Advancing Surgical Standards*, hal. 137-139
- Gabriel N. H. *et al.* 2017. American Joint Committee on Cancer (AJCC) Cancer Staging Manual, Eighth Edition. Breast. The American Colleges of Surgeon (ACS), hal. 589-634
- Gray E. *et al.* 2018. Survival Estimates Stratified by the Nottingham Prognostic Index for Early
- Guo W. *et al.* 2019. Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio for Breast Cancer Patients: An Updated Metaanalysis of 17079 Individuals. *Cancer Medicine*, hal. 4135-4148

- Jarroudi O. A. *et al.* 2019. Nottingham Prognostic Index is an Applicable Prognostic Tool in Non-Metastatic Triple-Negative Breast Cancer. *Asian Pacific Journal of Cancer Prevention*. Vol 20, hal. 1-2
- Junqueira L.C. & J.Carneiro, R.O. K. 2007. *Histologi Dasar*. Edisi ke-5. Basic Histology. Jakarta: EGC
- Koh C.H. *et al.* 2015. Utility of Pre-treatment Neutrophil–lymphocyte Ratio and Platelet–lymphocyte Ratio as Prognostic Factors in Breast Cancer. *British Journal of Cancer*. 113, 150–158
- Lu Q. *et al.* 2018. Clinical Implication of Platelet Lymphocyte Ratio and PD-L1 in Breast Cancer Patients. *Translational Cancer Research*. 7(3), hal. 659-667
- Momenimovahed, Z. & Salehiniya, H. 2019. Epidemiological characteristics of and risk factors for breast cancer in the world. *Breast Cancer - Targets and Therapy*, hal 151
- Notoatmodjo, S. 2010. *Metodelogi Penelitian Kesehatan*. Jakarta: Rineka Cipta
- Price Sylvia A, Wilson Lorraine M. 2012. *Patofisiologi: Konsep Klinis Proses-Proses Penyakit..* Jakarta: EGC
- Roger A. D. 2010. *Clinical Anatomy of the Breast*. Advanced Anatomical Services
- Sastroasmoro, S. 2011. *Dasar – Dasar Metodologi Penelitian Klinis*, Edisi 4. Jakarta: Sagung Seto, hal. 142
- Panigoro, S. *et al.* 2013. *Panduan Penatalaksanaan Kanker Payudara*. Komite Penanggulangan Kanker Indonesia. Kementrian Kesehatan Republik Indonesia, hal. 1
- Zhang M. *et al.* 2017. High Platelet-to-Lymphocyte Ratio Predicts Poor Prognosis and Clinicopathological Characteristics in Patients with Breast Cancer: A Meta-Analysis. *BioMed Research International*, hal. 1-2
- Zhu Y. *et al.* 2017. Platelet-lymphocyte Ratio Acts as an Indicator of Poor Prognosis in Patients with Breast Cancer. *Oncotarget*, Vol. 8.1: 1023-1030